NasdaqGS - Nasdaq Real Time Price USD

Phathom Pharmaceuticals, Inc. (PHAT)

Compare

6.94

-0.01

(-0.14%)

At close: January 10 at 4:00:01 PM EST

6.94

-0.00

(-0.01%)

After hours: 7:35:24 PM EST

Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)?

PGIM Jennison Health Sciences Fund recently released its third quarter 2024 investor letter. A copy of the letter can be downloaded here. Given concerns regarding the decreasing pace of U.S. employment and the associated concerns that U.S. interest rates may have been maintained at levels higher than necessary to moderate the pace of inflation, U.S. […]

Insider Monkey 29 days ago

PHAT
-0.14%
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Citizen Petition seeks correction of expiration date for New Chemical Entity (NCE) exclusivity on VOQUEZNA (vonoprazan) tablets Orange Book listingsPhathom believes applicable law mandates a 10-year NCE exclusivity period (from date of first approval of drug containing vonoprazan) benefitting all vonoprazan-based products, with exclusivity until May 3, 2032 FLORHAM PARK, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on d

GlobeNewswire last month

PHAT
-0.14%
Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround

Phathom Pharmaceuticals (PHAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks last month

PHAT
-0.14%
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know

Phathom Pharmaceuticals (PHAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks last month

PHAT
-0.14%
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

Phathom Pharmaceuticals Inc (PHAT) reports a significant revenue increase and strong market penetration for VOQUEZNA, despite ongoing financial challenges.

GuruFocus.com 2 months ago

PHAT
-0.14%
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of 15.92% and 30.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

PHAT
-0.14%
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Net revenues of $16.4 million reported for the third quarter 2024 compared to $7.3 million in the second quarter 2024, over 120% sequential quarterly increaseOver 143,000 prescriptions filled for VOQUEZNA® (vonoprazan) products, launch to date, a 138% increase since last quarterly reportCommercial access for VOQUEZNA tablets expanded, now covering over 80% of U.S. commercial livesManagement to host conference call today, November 7, 2024, at 8:30 am ET FLORHAM PARK, N.J., Nov. 07, 2024 (GLOBE NE

GlobeNewswire 2 months ago

PHAT
-0.14%
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in November and December: Guggenheim’s Inaugural Healthcare Innovation Conference in Boston, MADate: Tuesday, November 12, 2024Live Webcast: 9:30 am ETManagem

GlobeNewswire 2 months ago

PHAT
-0.14%
Investors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96%

If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly...

Simply Wall St. 2 months ago

PHAT
-0.14%
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Management to host conference call on Thursday, November 7, 2024, at 8:30 am ET FLORHAM PARK, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, November 7, 2024, to report its third quarter 2024 financial results and provide a business update. A live webcast and additio

GlobeNewswire 2 months ago

PHAT
-0.14%
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the company will present data from multiple investigational studies for its first-in-class treatment VOQUEZNA® (vonoprazan) tablets at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting, being held October 25-30 in Philadelphia,

GlobeNewswire 2 months ago

PHAT
-0.14%
Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

FLORHAM PARK, N.J., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten offering of 8,695,652 shares of its common stock and pre-funded warrants to purchase 2,608,922 shares of common stock. The shares of common stock are being sold at a price of $11.50 per share and the pre-funded warrants are being sold

GlobeNewswire 4 months ago

PHAT
-0.14%
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -4.17% and 29.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

PHAT
-0.14%
FBIO
Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly reportNet revenues of $7.3 million reported for the second quarter 2024 compared to $1.9 million in the first quarter 2024, greater than a 280% increaseVOQUEZNA (vonoprazan) tablets 10mg now FDA-approved and available to treat heartburn associated with Non-Erosive Gastroesophageal Reflux Disease (GERD) in adults – unlocking the entire GERD market of over 22 mill

GlobeNewswire 5 months ago

PHAT
-0.14%
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients

CVS Caremark, the largest pharmacy benefit manager (PBM) in the United States, added VOQUEZNA® (vonoprazan) tablets to its national formularies for its more than 26 million commercially insured members Over 116 million commercially covered lives are now estimated to have access to VOQUEZNA, the first major innovation in Gastroesophageal Reflux Disease (GERD) treatment in over 30 years and the only FDA-approved treatment of its kind available in the U.S. FLORHAM PARK, N.J., July 30, 2024 (GLOBE N

GlobeNewswire 5 months ago

PHAT
-0.14%
Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024

Management to host conference call on Thursday, August 8, 2024, at 8:30 am ET FLORHAM PARK, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, August 8, 2024, to report its second quarter 2024 financial results and provide an update on business progress. A live webcast a

GlobeNewswire 5 months ago

PHAT
-0.14%
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

VOQUEZNA is now approved and available to treat the largest category of Gastroesophageal Reflux Disease (GERD)VOQUEZNA met its primary endpoint in its Phase 3 pivotal trial by demonstrating a significant and rapid reduction of heartburn with daily treatmentVOQUEZNA represents the first major innovation in GERD treatment in over 30 years and the only FDA-approved treatment of its kind available in the U.S. A Media Snippet accompanying this announcement is available by clicking on this link. FLORH

GlobeNewswire 5 months ago

PHAT
-0.14%
Ready for Quick Gains? 7 Top Short-Squeeze Stocks to Watch Now

Retail investor interest in short squeeze stocks has grown considerably since the “meme stock” phenomenon of 2021. However, a stock doesn’t need to gain the “meme king” popularity of a GameStop (NYSE:GME) or an AMC Entertainment (NYSE:AMC) to become a profitable squeeze trade for investors. In many situations, all it takes is two things. First, a high level of short interest. What constitutes high short interest? Think 20%, 30%, 40%, or more of outstanding float sold short. Second, to trigger a

InvestorPlace 6 months ago

ABR

RILY

MPW
Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze

One of the fastest ways to make money on the stock market is to gamble on short-term contrarian positions against the shorting interest of a stock. Since every company’s proportion of shorted stock is publicly available, it’s pretty easy to see which companies are expected to lose value. However, short positions on stocks are speculative, like any other investment, and can become short-squeeze stocks in the blink of an eye. So, how does a shorted stock become a short squeeze stock? It all depend

InvestorPlace 7 months ago

BMEA

PHAT
-0.14%
Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting

First oral presentation of Phase 3 data evaluating the investigational use of VOQUEZNA® in Non-Erosive Reflux Disease (NERD)1New research on Erosive gastroesophageal reflux disease (GERD) demonstrating high health care resource utilization, real world treatment patterns in newly diagnosed patients and diagnostic accuracy of grading disease severity, to be presented2,3,4 FLORHAM PARK, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company

GlobeNewswire 7 months ago

PHAT
-0.14%

Performance Overview

Return	PHAT	S&P 500
YTD	-13.25%	-1.35%
1-Year	-16.69%	+22.51%
3-Year	-58.42%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Phathom Pharmaceuticals, Inc. (PHAT)

Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)?

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround

Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know

Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Investors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96%

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients

Phathom Pharmaceuticals to Report Second Quarter 2024 Financial Results and Provide Business Update on Thursday, August 8, 2024

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

Ready for Quick Gains? 7 Top Short-Squeeze Stocks to Watch Now

Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting

Performance Overview